MD An­der­son buys tech from Bel­licum; Tar­sus’ Ly­me dis­ease tri­al da­ta; Rigel takes Gavre­to

Plus, Oc­u­lar Ther­a­peu­tix’s pri­vate place­ment, Lim­maT­e­ch Bi­o­log­ics’ shigel­losis vac­cine da­ta and a col­lab­o­ra­tion be­tween Hox Ther­a­peu­tics and Ver­nalis.

MD An­der­son buys tech from Bel­licum: The Texas can­cer re­search in­sti­tu­tion said it has ac­quired “cer­tain as­sets” and IP from its Hous­ton neigh­bor, which last year start­ed a strate­gic re­view process. MD An­der­son will use the “safe­ty switch” tech in its cell ther­a­pies, and the can­cer cen­ter plans to ink non-ex­clu­sive li­cens­es with oth­er aca­d­e­m­ic groups and bio­phar­ma com­pa­nies so they can ac­cess it, as well. — Kyle LaHu­cik

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER